Found: 11
Select item for more details and to access through your institution.
Left ventricular mass predicts cardiac reverse remodelling in patients treated with empagliflozin.
- Published in:
- Cardiovascular Diabetology, 2023, v. 22, n. 1, p. 1, doi. 10.1186/s12933-023-01849-w
- By:
- Publication type:
- Article
The association between anthropometric indicators of obesity and cardiac reverse remodelling with empagliflozin in patients with type 2 diabetes and coronary artery disease.
- Published in:
- Diabetes, Obesity & Metabolism, 2023, v. 25, n. 9, p. 2765, doi. 10.1111/dom.15119
- By:
- Publication type:
- Article
Vascular repair and regeneration in cardiometabolic diseases.
- Published in:
- European Heart Journal, 2022, v. 43, n. 6, p. 450, doi. 10.1093/eurheartj/ehab758
- By:
- Publication type:
- Article
Restoration of blood vessel regeneration in the era of combination SGLT2i and GLP-1RA therapy for diabetes and obesity.
- Published in:
- Cardiovascular Research, 2023, v. 119, n. 18, p. 2858, doi. 10.1093/cvr/cvae016
- By:
- Publication type:
- Article
Effect of empagliflozin on cardiac remodelling in South Asian and non-South Asian individuals: insights from the EMPA-HEART CardioLink-6 randomised clinical trial.
- Published in:
- BMC Cardiovascular Disorders, 2023, v. 23, p. 1, doi. 10.1186/s12872-023-03549-5
- By:
- Publication type:
- Article
Efficacy of sodium–glucose cotransporter 2 inhibitors and angiotensin receptor–neprilysin inhibitors for heart failure in black patients: a systematic review and meta‐analysis of randomized controlled trials.
- Published in:
- European Journal of Heart Failure, 2023, v. 25, n. 4, p. 591, doi. 10.1002/ejhf.2825
- By:
- Publication type:
- Article
IGFBP7 and left ventricular mass regression: a sub‐analysis of the EMPA‐HEART CardioLink‐6 randomized clinical trial.
- Published in:
- ESC Heart Failure, 2023, v. 10, n. 3, p. 2113, doi. 10.1002/ehf2.14335
- By:
- Publication type:
- Article
Impact of diabetes duration on left ventricular mass regression with empagliflozin.
- Published in:
- ESC Heart Failure, 2023, v. 10, n. 3, p. 2134, doi. 10.1002/ehf2.14357
- By:
- Publication type:
- Article
Baseline neutrophil‐to‐lymphocyte ratio and efficacy of SGLT2 inhibition with empagliflozin on cardiac remodelling.
- Published in:
- ESC Heart Failure, 2023, v. 10, n. 3, p. 2127, doi. 10.1002/ehf2.14351
- By:
- Publication type:
- Article
SGLT2 inhibitors and cardiac remodelling: a systematic review and meta‐analysis of randomized cardiac magnetic resonance imaging trials.
- Published in:
- ESC Heart Failure, 2021, v. 8, n. 6, p. 4693, doi. 10.1002/ehf2.13645
- By:
- Publication type:
- Article
Surgical Treatment for Gerbode Defect Caused by Infective Endocarditis.
- Published in:
- Journal of Invasive Cardiology, 2021, v. 33, n. 12, p. E1009, doi. 10.25270/jic/21.00246
- By:
- Publication type:
- Article